131I联合抗甲亢药物治疗甲亢的疗效观察  

Observation on the Efficacy of 131I Combined with Antihyperthyroidism Drugs in the Treatment of Hyperthyroidism

作　　者：隆丽[1] LONG Li(Department of Endocrinology,Huaihua Fifth People's Hospital,Huaihua 418000,China)

机构地区：[1]怀化市第五人民医院内分泌科,湖南怀化418000

出　　处：《临床医学工程》2020年第6期753-754,共2页Clinical Medicine & Engineering

摘　　要：目的观察131I联合抗甲亢药物治疗甲亢的疗效,为甲亢患者的治疗提供临床依据。方法选择2018年5月至2019年5月我院收治的68例甲亢患者,按照治疗方法的不同分为两组各34例。对照组患者采用抗甲亢药物治疗,观察组患者采用131I联合抗甲亢药物治疗。比较两组的临床疗效及甲亢性心脏病发生率,比较两组的白细胞和肝功能酶学指标(ALT、 GGT、 AST)。结果观察组的总有效率为97.06%,显著高于对照组的76.47%(P <0.05)。观察组的甲亢性心脏病发生率为0.00%,显著低于对照组的14.71%(P <0.05)。观察组的白细胞计数、 ALT、 GGT、 AST分别为(6.0±2.0)×109/L、(18.6±9.2) U/L、(24.2±9.5) U/L、(19.7±3.1) U/L,显著低于对照组的(12.2±3.1)×109/L、(59.4±22.5) U/L、(84.5±30.2) U/L、(56.8±21.6) U/L (P <0.05)。结论131I联合抗甲亢药物治疗甲亢的临床疗效确切,可减少甲亢性心脏病的发生,值得临床应用。Objective To observe the efficacy of 131I combined with antihyperthyroidism drugs in the treatment of hyperthyroidism,and provide clinical basis for the treatment of hyperthyroidism patients.Methods 68 patients with hyperthyroidism admitted to our hospital from May 2018 to May 2019 were selected and divided into two groups according to different treatment methods,with 34 cases in each group.The control group was treated with antihyperthyroidism drugs,and the observation group was treated with 131I combined with antihyperthyroidism drugs.The clinical efficacy and incidence of hyperthyroid heart disease were compared between the two groups,and the white blood cell count and enzyme indicators of liver function(ALT,GGT,AST)were compared between the two groups.Results The total effective rate of the observation group was 97.06%,significantly higher than 76.47%of the control group(P<0.05).The incidence of hyperthyroid heart disease of the observation group was 0.00%,significantly lower than 14.71%of the control group(P<0.05).The white blood cell count,ALT,GGT,and AST of the observation group were(6.0±2.0)×10^9/L,(18.6±9.2)U/L,(24.2±9.5)U/L and(19.7±3.1)U/L respectively,significantly lower than(12.2±3.1)×10^9/L,(59.4±22.5)U/L,(84.5±30.2)U/L and(56.8±21.6)U/L of the control group,respectively(all P<0.05).Conclusions 131I combined with antihyperthyroidism drugs in the treatment of hyperthyroidism has definite clinical efficacy,and can reduce the incidence of hyperthyroid heart disease,which is worthy of clinical application.

关 键 词：甲亢 131I 抗甲亢药物 疗效 

分 类 号：R581.1[医药卫生—内分泌]